First National Bank of Omaha Acquires 3,092 Shares of Stryker Corporation $SYK

Posted by George Bondi on Aug 19th, 2026

First National Bank of Omaha grew its holdings in shares of Stryker Corporation (NYSE:SYK – Free Report) by 61.4% in the 2nd quarter, HoldingsChannel reports. The firm owned 8,129 shares of the medical technology company’s stock after acquiring an additional 3,092 shares during the quarter. First National Bank of Omaha’s holdings in Stryker were worth $2,639,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sankala Group LLC bought a new position in Stryker in the 4th quarter worth about $26,000. Godfrey Financial Associates Inc. bought a new stake in shares of Stryker during the 4th quarter valued at about $26,000. United Financial Planning Group LLC bought a new position in shares of Stryker in the third quarter worth approximately $27,000. Atlas Capital Advisors Inc. bought a new position in shares of Stryker in the fourth quarter worth approximately $27,000. Finally, DJE Kapital AG purchased a new stake in Stryker in the fourth quarter valued at approximately $28,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Up 0.1%

Shares of NYSE SYK opened at $331.96 on Wednesday. The stock has a market capitalization of $127.33 billion, a P/E ratio of 34.40, a PEG ratio of 2.16 and a beta of 0.76. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The firm’s 50 day simple moving average is $325.56 and its two-hundred day simple moving average is $333.05. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same period in the previous year, the business posted $3.13 EPS. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts expect that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is currently 36.48%.

Insider Buying and Selling at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 315,370 shares of company stock worth $98,463,501 over the last three months. Company insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

SYK has been the subject of a number of research reports. Needham & Company LLC cut their price target on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Raymond James Financial set a $370.00 price objective on shares of Stryker in a research report on Friday, July 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. UBS Group began coverage on shares of Stryker in a research report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 target price for the company. Finally, Argus set a $370.00 price target on Stryker in a research report on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Get Our Latest Report on Stryker

Stryker Company Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.